切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2015, Vol. 09 ›› Issue (03) : 188 -192. doi: 10.3877/cma.j.issn.1674-0793.2015.03.004

所属专题： 文献；

论著

18F-FDG PET/CT成像观察西妥昔单抗对结直肠癌裸鼠移植肿瘤影响的实验研究
李雯雯1, 赵广银1, 张兆1, 龙成露1, 黄颖1, 苏乔1,†()   
  1. 1. 510080　广州,　中山大学附属第一医院动物实验中心
  • 收稿日期:2014-12-25 出版日期:2015-06-01
  • 通信作者: 苏乔
  • 基金资助:
    广东省科技计划资助项目(2010B060500007)

Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by 18F-FDG PET/CT

Wenwen Li1, Guangyin Zhao1, Zhao Zhang1, Chenglu Long1, Ying Huang1, Qiao Su1,†()   

  1. 1. Animal Laboratory Center, the First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China
  • Received:2014-12-25 Published:2015-06-01
  • Corresponding author: Qiao Su
  • About author:
    Corresponding author: Su Qiao, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李雯雯, 赵广银, 张兆, 龙成露, 黄颖, 苏乔. 18F-FDG PET/CT成像观察西妥昔单抗对结直肠癌裸鼠移植肿瘤影响的实验研究[J]. 中华普通外科学文献(电子版), 2015, 09(03): 188-192.

Wenwen Li, Guangyin Zhao, Zhao Zhang, Chenglu Long, Ying Huang, Qiao Su. Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by 18F-FDG PET/CT[J]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(03): 188-192.

目的

建立结直肠癌裸鼠移植肿瘤模型,用小动物18F-FDG PET/CT技术评价西妥昔单抗对人结直肠癌移植肿瘤的影响。

方法

BALB/c裸鼠皮下分别接种人结直肠癌细胞HCT116、LIM1215,建立HCT116与LIM1215两种荷瘤裸鼠模型。将成瘤后的模型分为对照组和西妥昔单抗治疗组(n=5),并且全程观察肿瘤体积变化情况。给药1周后采用小动物18F-FDG PET/CT技术评价实体肿瘤模型,并测量各组织与器官的18F-FDG最大每克组织摄取率。

结果

小动物18F-FDG PET/CT成像显示裸鼠接种部位肿瘤内放射性摄取值增高,LIM1215与HCT116肿瘤模型的治疗组与对照组相比,肿瘤/组织或器官18F-FDG摄取比率均普遍降低,其中肿瘤/颈肌、肿瘤/心脏与肿瘤/肝脏比值差异有统计学意义(P=0.047、0.008、0.024),但两种肿瘤模型的肿瘤体积测量结果均显示,治疗组与对照组的肿瘤生长趋势差异无统计学意义。

结论

在西妥昔单抗对结直肠癌裸鼠移植肿瘤模型的治疗实验中,西妥昔单抗对肿瘤生长尚未有明显抑制作用时,小动物18F-FDG PET/CT可监测到肿瘤葡萄糖代谢的变化。

关键词: 18F-FDG, PET/CT, 西妥昔单抗, 结直肠癌, 裸鼠, 小动物
Objective

To observe the effect of cetuximab in tumor with small animal PET/CT by establishing the xenogenous implant model of colorectal cancer in nude mice.

Methods

HCT116 and LIM1215 tumor-bearing nude mouse models were developed by subcutaneous implantation of HCT116 and LIM1215 cells into BALB/c-nu mice. The tumor models were divided into the control group and cetuximab treatment group (n=5), and to observe the growth of tumor. Then the tumor models were evaluated by small animal 18F-FDG PET/CT after one week, and we measured the maximum percentage injected dose per gram from tissue and organ at the same time.

Results

The uptake of 18F-FDG in tumor tissues was significantly higher than that in normal tissues. Compared with control group, the 18F-FDG uptake rates of tumors/tissue or organ were generally lower in treatment group, which had significant difference in the ratio of tumor/neck, tumor/tumor and heart/liver (P=0.047、0.008、0.024). But the growth trends of tumor volume had no significant difference between treatment group and control group.

Conclusion

Small animal 18F-FDG PET/CT can monitor the change of glucose metabolism in tumor, while there is no obvious inhibitory effect in tumor growth with cetuximab treating xenogenous implant nude mice of colorectal cancer.

Key words: 18F-FDG, PET/CT, Cetuximab, Colorectal cancer, Nude mice, Small animal
图1 各组肿瘤模型小动物PET显像
表1 各组肿瘤模型的肿瘤/组织或器官18F-FDG摄取比率
组别 肿瘤／棕色脂肪 肿瘤／颈肌 肿瘤／心脏 肿瘤／脑 肿瘤／肾脏 肿瘤／肝脏 肿瘤／哈氏腺
A组 0.97±0.18 0.67±0.18 1.14±0.28 0.69±0.11 2.01±0.37 1.22±0.31 1.27±0.10
B组 0.42±0.25 0.41±0.07 a，b 0.23±0.07 b 0.36±0.19 1.01±0.51 1.05±0.68 0.54±0.30
C组 1.67±0.62 1.51±0.43 2.33±0.65 0.83±0.23 1.70±0.45 1.50±0.52 1.41±0.41
D组 0.75±0.35 0.86±0.35 1.31±0.58 0.75±0.20 1.49±0.40 1.34±0.32 c 1.03±0.42
图2 各组肿瘤/组织或器官18F-FDG摄取比率的柱状比较图
图3 各组荷瘤裸鼠肿瘤体积变化
[1]
汪建平.重视结直肠癌流行病学研究[J].中国实用外科杂志, 2013, 33(8): 622-624.
[2]
Bellomi M, Rizzo S, Travaini LL, et al. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer[J]. Radiol Med, 2007, 112(5): 681-690.
[3]
Sotelo MJ, García-Paredes B, Aguado C, et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer[J]. World J Gastroenterol, 2014, 20(15): 4208-4219.
[4]
Spindler KL, Christensen IJ, Nielsen HJ, et al. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer [J]. Tumor Biol, 2015 Jan 23. [Epub ahead of print]
[5]
Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer[J]. Drugs, 2004, 64 (1): 109-118.
[6]
VanDijk LK, Boerman OC, Franssen GM, et al. Cetuximab-F(ab′)2-SPECT and FDG-PET for prediction and response monitoring of combined modality treatment of human head and neck carcinomas in a mouse model[J]. J Nucl Med, 2014 Dec 31. [Epub ahead of print]
[7]
Aliaga A, Rousseau JA, Cadorette J, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18] fluoro-D-glucose in murine models of breast cancer[J]. Mol Imaging Biol, 2007, 9(3): 144-150.
[8]
Monazzam A, Josephsson R, Blomqvist C, et al. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer[J]. Breast Cancer Res, 2007, 9(4): 45.
[9]
Liu FY, Yen TC, Wang JY, et al. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy[J]. Clin Nucl Med, 2015, 40(3): 200-205.
[10]
Grybauskas M, Daisne JF, Aleknavičius E, et al. Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx[J]. Medicina (Kaunas), 2014, 50(4): 245-248.
[11]
Zerizer I, Al-Nahhas A, Towey D, et al. The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9): 1391-1399.
[12]
Koolen BB, Pengel KE, Wesseling J, et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1): 32-40.
[13]
Chung HW, Lee EJ, Cho YH, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma[J]. J Cancer Res Clin Oncol, 2010, 136(12): 1929-1935.
[14]
Tsuji AB, Sogawa C, Sugyo A, et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts[J]. Nucl Med Biol, 2009, 36(4): 379-388.
[1] 刘付有欢, 吴秀芹, 邓翠婷, 苏青. 基于模型的西妥昔单抗治疗胃癌细胞系的反应和耐药因素分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 385-388.
[2] 单兴利, 王栋, 邢念增, 肖泽均, 李亚健. 68Ga-PSMA-PET/CT对前列腺癌盆腔淋巴结转移诊断价值的研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 214-218.
[3] 彭国兵, 费建平. 影响患者永久性结肠造口的状况及因素[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(03): 264-268.
[4] 陈润芝, 杨东梅, 徐慧婷. 信迪利单抗联合索凡替尼后线治疗MSS型BRAF突变的转移性结肠癌：个案报道并文献复习[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 431-435.
[5] 鄂一民, 孙司正, 范小彧, 喻春钊. 结直肠癌粪便筛查的现状与展望[J]. 中华结直肠疾病电子杂志, 2023, 12(04): 331-336.
[6] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[7] 王小娜, 谭微, 李悦, 姜文艳. 预测性护理对结直肠癌根治术患者围手术期生活质量、情绪及并发症的影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 525-529.
[8] 刘代江, 蒋俊艳, 万晓强, 马莎英. 结直肠癌肝转移患者生存状况及预后影响因素分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 284-288.
[9] 王健, 赵海剑, 孙静, 张晓雨, 陈柏羽. LncRNA SNHG4表达与结直肠癌预后的关系[J]. 中华消化病与影像杂志(电子版), 2023, 13(03): 139-144.
[10] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[11] 王飞飞, 王光林, 孟泽松, 李保坤, 曹龙飞, 张娟, 周超熙, 丁源一, 王贵英. 敲低IMPDH1对结肠癌SW480、HT29细胞生物功能的影响[J]. 中华临床医师杂志(电子版), 2023, 17(08): 884-890.
[12] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
[13] 王亚丹, 吴静, 黄博洋, 王苗苗, 郭春梅, 宿慧, 王沧海, 王静, 丁鹏鹏, 刘红. 白光内镜下结直肠肿瘤性质预测模型的构建与验证[J]. 中华临床医师杂志(电子版), 2023, 17(06): 655-661.
[14] 王延召, 牛鹏飞, 丁长民, 高庆坤, 高兆亚, 安柯, 翟志超, 曾庆敏, 黄文生, 雷福明, 顾晋. 结直肠癌致腹壁巨大缺损的一期修补经验（附13例报告）[J]. 中华临床医师杂志(电子版), 2023, 17(05): 557-561.
[15] 任鹏涛, 郝英豪, 阮红训, 秦晓宁, 张苑, 李猛. Lnczc3h7a靶向CTHRC6对肠癌细胞的增殖和迁移的影响[J]. 中华临床医师杂志(电子版), 2023, 17(03): 320-325.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号